ENA Respiratory has appointed Melissa Faris as an independent Non-Executive Director, bringing extensive experience from her roles at OMass Therapeutics and GSK, where she led business development in immunology and infectious diseases. Her appointment is expected to enhance ENA’s strategic direction as it advances the clinical development of INNA-051, a novel antiviral host defense enhancer aimed at minimizing the impact of symptomatic viral respiratory infections.

The significance of this development lies in ENA’s innovative approach to tackling respiratory viral infections through host defense enhancers. INNA-051 operates as a potent agonist of toll-like receptor 2/6 (TLR2/6), which is crucial for recognizing pathogens and enhancing innate immune responses. The drug has shown promising results in a Phase IIa proof-of-principle study, demonstrating accelerated virus clearance and stimulation of IFN Type I & III responses. This positions INNA-051 as a potential therapeutic option for vulnerable populations, including the elderly and those with chronic conditions, where existing vaccines and antivirals may fall short.

The appointment of Faris underscores the growing recognition of the need for innovative antiviral strategies in the face of emerging respiratory viruses. This shift could significantly influence research paradigms in the field, particularly in the development of virus-agnostic therapies. As ENA continues to advance INNA-051, the integration of Faris’s expertise may expedite timelines for clinical trials and regulatory approvals, ultimately paving the way for new treatment modalities that enhance healthspan and address unmet medical needs in respiratory health.

Source: globenewswire.com